Accent Therapeutics Announces $75 Million Series C Financing to …

LEXINGTON, Mass., January 23, 2024 – Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the …

CouponFollow Extension

$75
OFF

Accent Therapeutics Announces $75 Million Series C Financing To …

6 days from now

LEXINGTON, Mass., January 23, 2024 – Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the …

accenttx.com

$75
OFF

Accent Therapeutics Announces $75 Million Series C Financing To …

6 days from now

Jan 23, 2024 · Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the completion of a $75 million …

yahoo.com

$75
OFF

Accent Therapeutics Announces $75 Million Series C Financing

6 days from now

LEXINGTON, Mass., Jan. 23, 2024 /PRNewswire/ -- Accent Therapeutics a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today …

biospace.com

$75
OFF

Accent Therapeutics Raises $75M In Series C Funding Round

6 days from now

Jan 23, 2024 · Biopharmaceutical company Accent Therapeutics has raised $75 million in a series C financing round, with the aim of using the funds to advance two of its precision oncology …

labpulse.com

$75
OFF

Bristol Myers Squibb, J&J Fund Accent Therapeutics’ $75 Million …

6 days from now

Jan 23, 2024 · Accent Therapeutics has secured $75 million in a Series C investment round, the company announced Tuesday morning. CEO Shakti Narayan said the funding would get the …

bizjournals.com

$75
OFF

$75 Million Series C Propels Accent's Small Molecule Cancer Drive

6 days from now

Jan 23, 2024 · Accent Therapeutics, a US biopharma seeking to develop a new class of small molecule precision cancer therapies, has announced the completion of a $75 million Series C …

thepharmaletter.com

$75
OFF

Pharmas Back Accent’s Plan To Make RNA-targeting Cancer Drugs

6 days from now

Jan 23, 2024 · Accent Therapeutics has raised a $75 million Series C round, the company announced Tuesday in a sign of continued investor interest in chemical drugs that target RNA …

biopharmadive.com

$75
OFF

Accent Therapeutics Raises $75M In Series C Funding Round

6 days from now

Jan 23, 2024 · NEW YORK – Accent Therapeutics on Tuesday announced it has raised $75 million in a Series C financing round, and that it will put the funds toward advancing its …

precisionmedicineonline.com

$75
OFF

Accent Therapeutics Raises $75M In Series C Funding - FinSMEs

6 days from now

Jan 23, 2024 · Accent Therapeutics, a Lexington, MA-based biopharmaceutical company focused on small molecule precision cancer therapies, raised $75M in Series C funding.. The round …

finsmes.com

$75
OFF

Accent Therapeutics Announces $75 Million Series C Financing To …

6 days from now

Financing led by Mirae Asset Capital Life Science with participation from additional new and existing investors. Funds will support advancement of lead programs through early clinical …

epicos.com

$75
OFF

Accent Therapeutics Completes $75M Series C Financing

6 days from now

Lexington, MA, January 23, 2024 (PRNewswire) -- Accent Therapeutics has successfully concluded its Series C financing, securing a total of $75 million. The funding round was …

jacobsmgt.com

$75
OFF

Accent Therapeutics: $75 Million To Pioneer A New Class Of Small ...

6 days from now

Jan 23, 2024 · Accent Therapeutics - a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies - recently announced the completion of a $75 …

pulse2.com

$75
OFF

Two More Pharmas Practice Their Accent, Invest In $75M Series C …

6 days from now

Jan 23, 2024 · Accent Therapeutics has tacked on two more Big Pharma backers, with J&J's venture arm and BMS joining the biotech's $75 million series C. The startup previously added …

fiercebiotech.com

$75
OFF

Accent Therapeutics Closes $75 Million Series C Financing

6 days from now

Jan 23, 2024 · Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the completion of a $75 million …

citybiz.co

$75
OFF

Accent Closes Series C Financing To Advance Cancer Programs

6 days from now

Jan 26, 2024 · Accent Therapeutics Inc. has completed a $75 million series C financing to support progression of its lead programs through early clinical development. BioWorld Science …

bioworld.com

$75
OFF

Series C - Accent Therapeutics - 2024-01-23 - Crunchbase

6 days from now

Jan 23, 2024 · The Daily News — Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies News • Jan 23, 2024 BioSpace — …

crunchbase.com

$75
OFF

Accent Therapeutics Announces $75 Million Series C Financing …

6 days from now

Jan 23, 2024 · Financing led by Mirae Asset Capital Life Science with participation from additional new and existing investors Funds will support advancement of lead programs through early …

yourbigsky.com

FAQs about Accent Therapeutics Announces $75 Million Series C Financing to … Coupon?

Does Accent Therapeutics have a series C financing?

1.23.24 Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies Financing led by Mirae Asset Capital Life Science with participation from additional new and existing investors ...

Who invested in Accent Therapeutics?

Accent Therapeutics also brought in new investors, including Bristol Myers Squibb, Johnson & Johnson Innovation – JJDC Inc., Mirae Asset Capital and Mirae Asset Venture Investment. Never miss a life sciences story: Sign up for Boston Business Journal's emails to get the latest business news in your inbox twice a day. ...

Is accent launching IND-enabling studies for KIF18A in 2024?

Accent is planning to initiate IND-enabling studies for KIF18A in the first half of 2024. Accent Therapeutics is pioneering a new class of small molecule precision cancer therapies targeting critical intracellular dependencies that span multiple types of cancer. ...

Will a Lexington cancer biotech get Series C funding?

A Lexington cancer biotech has attracted Series C funding from the likes of Bristol Myers Squibb, Johnson & Johnson’s venture capital arm and a newly launched biotech VC firm. ...

How many employees does accent have?

The company has about 45 employees and is located at 1050 Waltham St. in Lexington. Naveen Krishnan, managing director of Mirae Asset Capital Life Science, and Sean Evans of JJDC are expected to join Accent’s board of directors. Narayan said the company’s focus from its founding in 2018 has been on RNA modifications. ...

Where is accent based?

Never miss a life sciences story: Sign up for Boston Business Journal's emails to get the latest business news in your inbox twice a day. Accent is discovering and developing oral oncology treatments. The company has about 45 employees and is located at 1050 Waltham St. in Lexington. ...